Novo Nordisk

Follow the facts.

--- HEADER PLACEHOLDER CONTENT SECTION ---

NovoSeven^® RT is used to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia.

Trust
the facts.

Be confident in your
treatment choice.

NovoSeven^® RT

SEVENFACT

NovoSeven^® RT has over 30 years of clinical and real-world experience in people with hemophilia B with inhibitors.^a

SEVENFACT DOES NOT
It was studied in two people with Hemophilia B with inhibitors in the PERSEPT 1 clinical trial.

NovoSeven^® RT is approved for use in all ages.^b

SEVENFACT IS NOT
It is only approved for adults and adolescents 12 years and older.

NovoSeven^® RT is approved for use before, during, and after surgery and procedures.

SEVENFACT IS NOT

NovoSeven^® RT is safe when used with Hemlibra.^c

SEVENFACT IS NOT

NovoSeven^® RT is the only rFVIIa with 30+ years of experience controlling severe bleeds.^a

SEVENFACT IS NOT
Three severe bleeds of 468 were studied in the PERSEPT 1 clinical trial.

^aFor people with hemophilia A or B with inhibitors.

^bIn people with acquired hemophilia, it is only indicated for adults.

^cNovoSeven^® RT is the only rFVIIa that has clinical experience for use with Hemlibra.

When making choices about a treatment with your doctor,
the facts speak for themselves.

Why NovoSeven^® RT?

Selected Important Safety Information

What is the most important information I should know about NovoSeven^® RT?

NovoSeven^® RT may cause serious side effects, including:

•

Serious blood clots that form in veins and arteries with the use of NovoSeven^® RT have been reported

•

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function

•

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven^® RT

Please click here or scroll below for additional Important Safety Information.

Miguel is a devoted dad with a busy lifestyle.

He also lives with hemophilia B with inhibitors.
See Miguel’s Story. Miguel has been choosing NovoSeven^® RT as his rFVIIa treatment for over 20 years. Why?

NovoSeven^® RT is:

90% effective in all severe bleeding episodes^a

Room temperature stable and travel ready^b

Fast to mix with our MixPro^® device. Fast to infuse. Fast to control bleeds^c

Approved for use before, during, and after surgery

^aData shown from compassionate use program and 2 clinical studies in patients with hemophilia A or B with or without inhibitors or acquired hemophilia.

^bNovoSeven^® RT should be stored between 36°F and 77°F.

^cAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.

Get the Facts

What is NovoSeven^® RT?

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

•

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions

•

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information (cont’d)

•

You should not use NovoSeven^® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven^® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven^® RT?

•

Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:

	◦	congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
	◦	are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
	◦	history of heart or blood vessel diseases

•

Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven^® RT?

•

The most common and serious side effects are blood clots

•

Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information.

NovoSeven^® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1-877-744-2579.

NovoSeven^® and MixPro^® are registered trademarks of Novo Nordisk Health Care AG.
All other trademarks, registered or unregistered, are the property of their respective owners.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US21NSVN00090 December 2021

--- FOOTER PLACEHOLDER CONTENT SECTION ---